Grufity logoGrufity logo
Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
PSTV

PSTV - Plus Therapeutics Inc Stock Price, Fair Value and News

2.21USD-0.04 (-1.78%)Market Closed

Market Summary

PSTV
USD2.21-0.04
Market Closed
-1.78%

PSTV Alerts

  • 5 major insider buys recently.

PSTV Stock Price

View Fullscreen

PSTV RSI Chart

PSTV Valuation

Market Cap

9.4M

Price/Earnings (Trailing)

-0.8

Price/Sales (Trailing)

32.09

Price/Free Cashflow

-0.8

PSTV Price/Sales (Trailing)

PSTV Profitability

Return on Equity

243.37%

Return on Assets

-209.43%

Free Cashflow Yield

-124.32%

PSTV Fundamentals

PSTV Revenue

Revenue (TTM)

303.0K

PSTV Earnings

Earnings (TTM)

-11.8M

Earnings Growth (Yr)

32.13%

Earnings Growth (Qtr)

14.41%

Breaking Down PSTV Revenue

Last 7 days

2.3%

Last 30 days

24.9%

Last 90 days

10.5%

Trailing 12 Months

-44.5%

How does PSTV drawdown profile look like?

PSTV Financial Health

Current Ratio

0.41

Debt/Equity

-0.78

Debt/Cashflow

-3.05

PSTV Investor Care

Shares Dilution (1Y)

77.07%

Diluted EPS (TTM)

-2.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2020000303.0K
20192.8M02.4M3.2M
20183.6M4.0M3.1M3.0M
20176.2M5.0M4.4M3.7M
20166.7M6.6M6.7M6.7M
20154.8M5.7M6.9M6.0M
20146.0M6.1M5.0M5.0M
20139.6M8.5M8.8M7.3M
20128.1M7.6M6.8M8.7M
20116.8M7.1M8.3M8.0M
201008.5M8.1M7.7M
20090008.9M
Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Plus Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 08, 2024
clowes howard
bought
20,000
2.04
9,804
-
May 08, 2024
sims andrew john hugh macintyre
bought
10,000
2.04
4,902
chief financial officer
May 08, 2024
petersen greg
bought
25,000
2.04
12,255
-
May 08, 2024
hedrick marc h
bought
25,000
2.04
12,255
chief executive officer
May 08, 2024
hawkins richard j
bought
10,000
2.04
4,902
-
May 08, 2024
lenk robert p
bought
8,500
2.04
4,167
-
Nov 20, 2023
hedrick marc h
sold
-4,052
1.9597
-2,068
chief executive officer
Nov 16, 2023
lenk robert p
bought
1,950
1.95
1,000
-
Nov 15, 2023
lenk robert p
bought
1,770
1.77
1,000
-
Nov 13, 2023
lenk robert p
bought
5,720
1.43
4,000
-

1–10 of 45

Which funds bought or sold PSTV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
CITADEL ADVISORS LLC
reduced
-36.4
-10,812
19,330
 -%
May 15, 2024
Tower Research Capital LLC (TRC)
added
569
5,912
6,913
 -%
May 14, 2024
Ground Swell Capital, LLC
sold off
-100
-25,602
-
 -%
May 13, 2024
RENAISSANCE TECHNOLOGIES LLC
reduced
-47.27
-27,000
31,000
 -%
May 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
added
10.25
5,308
52,819
 -%
May 13, 2024
UBS Group AG
sold off
-100
-15,573
-
 -%
May 10, 2024
JPMORGAN CHASE & CO
added
1.01
4.00
181
 -%
May 10, 2024
VANGUARD GROUP INC
unchanged
-
1,787
58,737
 -%
May 10, 2024
BlackRock Inc.
unchanged
-
382
12,563
 -%
May 10, 2024
OSAIC HOLDINGS, INC.
unchanged
-
8.00
240
 -%

1–10 of 13

Are Funds Buying or Selling PSTV?

Are funds buying PSTV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PSTV
No. of Funds

PSTV Alerts

Unveiling Plus Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
parkman healthcare partners llc
1.7%
583,467
SC 13G/A
Feb 11, 2022
intracoastal capital, llc
1.9%
3e+05
SC 13G/A
Feb 04, 2022
parkman healthcare partners llc
7.4%
1,508,508
SC 13G
Feb 04, 2022
hudson bay capital management lp
3.46%
550,000
SC 13G/A
Feb 26, 2021
nanotx, corp.
4.83%
230,769
SC 13G/A
Feb 26, 2021
nanotx, corp.
4.83%
230,769
SC 13G/A
Feb 10, 2021
hudson bay capital management lp
9.99%
530,474
SC 13G/A
Jan 29, 2021
intracoastal capital, llc
5.9%
3e+05
SC 13G/A
May 14, 2020
nanotx, corp.
5.61%
230,769
SC 13G
Feb 14, 2020
anson funds management lp
4.9%
198,034
SC 13G/A

Recent SEC filings of Plus Therapeutics Inc

View All Filings
Date Filed Form Type Document
May 15, 2024
10-Q
Quarterly Report
May 15, 2024
8-K
Current Report
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 10, 2024
4
Insider Trading
May 09, 2024
8-K
Current Report
Mar 14, 2024
8-K
Current Report

Peers (Alternatives to Plus Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
MRNA
50.9B
6.8B
 28.49% 6.05%
-8.53
7.44
 -64.45% -224.75%
HILS
22.5B
216.3K
 -0.77% 465779.94%
-2.5K
104.0K
 - -8.13%
ALNY
18.9B
2.0B
 2.79% -21.33%
-56.9
9.43
 75.20% 68.82%
BMRN
14.7B
2.5B
 -14.30% -15.94%
71.65
5.96
 13.74% 186.89%
INCY
12.8B
3.8B
 8.33% -10.25%
17.2
3.4
 8.58% 129.81%
MID-CAP
BBIO
5.6B
107.9M
 20.58% 115.45%
-10.31
48.09
 54.84% -28.31%
APLS
5.0B
524.1M
 -13.99% -52.79%
-12.02
9.57
 394.93% 39.61%
AXSM
3.6B
251.0M
 9.96% -0.29%
-12.28
14.5
 73.58% -86.73%
ARWR
3.1B
240.7M
 9.94% -31.73%
-6.53
12.77
 -1.03% -213.43%
ACAD
2.4B
813.8M
 -14.08% -36.34%
-1.4K
3
 56.43% 98.83%
SMALL-CAP
CPRX
1.9B
411.3M
 3.06% 35.16%
29.91
4.73
 60.38% -34.49%
NVAX
1.8B
996.6M
 234.45% 75.34%
-4.58
1.83
 -26.66% 65.49%
CRBP
480.9M
881.7K
 21.10% 351.81%
-14.25
481.06
 -77.61% 33.36%
INO
310.9M
4.9M
 8.40% 53.85%
-2.49
63.89
 -54.97% 48.23%
IBIO
17.1M
2.1M
 4.76% 108.64%
-0.74
7.61
 -13.45% 69.54%

Plus Therapeutics Inc News

Latest updates
MSN • 16 May 2024 • 06:25 am
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024
Investing.com Australia • 11 May 2024 • 05:38 am
Lenk Robert P buys $8.5k in Plus Therapeutics shares
Investing.com • 10 May 2024 • 03:56 pm
Plus Therapeutics CFO acquires $10,000 in company stock By Investing.com
Investing.com • 10 May 2024 • 01:30 pm
Plus Therapeutics director purchases $25,000 in company stock By Investing.com
Investing.com • 10 May 2024 • 01:30 pm
Plus Therapeutics CEO buys $25,000 in company stock By Investing.com
Yahoo Finance • 22 Apr 2024 • 07:00 am
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
TipRanks • 2 months ago
Plus Therapeutics CEO's Insightful Presentation Now Available.com - TipRanks
Yahoo Finance • 2 months ago
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Yahoo Finance • 2 months ago
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on ...
Business Wire • 8 months ago
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

Plus Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2020Q42019Q42019Q32019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q42016Q32016Q22016Q12015Q42015Q32015Q22015Q12014Q4
Revenue-100.0%-1,1885267377134548999178671,3065311,0181,5611,8791,6991,5851,5561,7111,8479022,469
Gross Profit------23030.0015229.00-20.00262-1255211135417667652643183051,053
Operating Expenses-0.2%3,3953,4012,0912,9032,5782,6812,745--------------
  S&GA Expenses-53.9%2,2994,98594.0011447.00118185294-------------
  R&D Expenses-36.6%1,0961,7299211,4261,6361,2261,2671,395-------------
Interest Expenses-39.3%229378366515543513444--------------
Net Income-505.8%-3,587884526-3,150-2,236-2,330-3,659--------------
Net Income Margin-Infinity%-27.20*--------------------
Free Cashflow-Infinity%-3,238--------------------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-50.6%5,62111,38813,27814,19715,63823,86723,10421,27124,51621,98124,75020,83418,33612,10511,65313,90420,96723,22925,7158,88424,616
  Current Assets-57.2%4,2139,83411,58412,36413,62921,81720,87918,88922,10419,72422,09718,00115,4469,1758,64910,79317,69719,82522,2645,2608,462
    Cash Equivalents-66.1%2,9018,55411,00610,89512,72318,12020,26618,09021,23918,40021,28017,16114,4478,3467,6269,26616,06117,55216,8344,5303,872
  Inventory---------------107107107107107107107
  Net PPE-11.7%8009061,0091,1431,2761,3241,4531,5601,5581,4771,6461,7381,8251,8201,9432,0142,0962,1792,2092,2972,384
  Goodwill0%372372372372372372372372372372372372372372372372372372372372372
Liabilities-17.9%10,45812,73610,65611,53512,96217,42211,70011,5929,87411,1459,9958,8898,8239,0749,03210,60420,88222,06925,55515,16020,759
  Current Liabilities-3.1%10,39910,72710,53811,39912,79611,8527,4206,9714,9215,8709,4888,3548,3158,5398,4049,77314,98814,48614,42713,92318,295
  Long Term Debt------3,7864,1084,4194,7185,005-----------
    LT Debt, Current-9.7%3,5903,9764,3484,7095,0571,6081,6081,6081,6081,6086,7526,6186,4866,3356,1816,02611,18211,06010,93710,81314,371
    LT Debt, Non Current------3,7864,1084,4194,7185,005-----------
Shareholder's Equity-258.8%-4,837-1,3482,6222,6622,6766,44511,4049,67914,64210,83614,75511,9459,5133,0312,6213,30085.001,160160-3,857
  Retained Earnings-0.7%-483,762-480,501-476,700-473,472-471,990-467,185-461,527-456,300-451,026-446,910-442,755-439,000-436,231-433,511-429,924-428,196-426,357-425,270-426,154-426,680-417,533
  Additional Paid-In Capital0.0%479,420479,274479,308476,131474,630473,628472,899465,965465,646457,730457,495450,964445,734436,535432,540431,492426,438426,426426,311420,404420,312
Accumulated Depreciation-100.0%-2,536---1,960---1,415---1,387---1,021---
Shares Outstanding-5.7%4,2644,5234,5232,8802,4082,2401,5861,4841,4341,034731753551450293------
Float----5,800---12,100---30,800---5,400---5,400-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-139.2%-4,500-1,881-2,370-2,807-5,793-2,234-4,222-2,640-3,876-2,624-2,251-2,399-3,006-3,224-2,299-1,409-1,5021,036-2,522-1,150-3,270
  Share Based Compensation3.5%14614114814014013012916718018118013810798.0094.0043.0012.0021.0029.0028.0049.00
Cashflow From Investing-766.7%-364-42.00-10.00-11.00-97.00-11.00-33.00-138-5772.00-4.004.00-84.00-56.00-14.00-412-11.00-59.00-2.005,637-6.00
Cashflow From Financing-46.7%-776-5292,52096149399.006,431-3717,292-2586,3745,1099,1914,000673-4,974-18.00-25914,424-3,4251,891
  Buy Backs-374--------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PSTV Income Statement

2024-03-31
CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 2,763,000$ 2,983,000
General and administrative2,213,0002,245,000
Total operating expenses4,976,0005,228,000
Operating loss(3,299,000)(4,722,000)
Other income (expense):  
Interest income72,00051,000
Interest expense(34,000)(134,000)
Total other expense38,000(83,000)
Net loss$ (3,261,000)$ (4,805,000)
Net loss per share, basic$ (0.75)$ (2.07)
Net loss per share, diluted$ (0.75)$ (2.07)
Basic weighted average shares used in calculating net loss per share attributable to common stockholders4,321,7312,320,017
Diluted weighted average shares used in calculating net loss per share attributable to common stockholders4,321,7312,320,017
Grant [Member]  
Revenue$ 1,677,000$ 506,000

PSTV Balance Sheet

2024-03-31
CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 2,901,000$ 8,554,000
Investments323,000 
Other current assets989,0001,280,000
Total current assets4,213,0009,834,000
Property and equipment, net800,000906,000
Operating lease right-use-of assets171,000202,000
Goodwill372,000372,000
Intangible assets, net33,00042,000
Other assets32,00032,000
Total assets5,621,00011,388,000
Current liabilities:  
Accounts payable and accrued expenses6,447,0006,631,000
Operating lease liability115,000120,000
Deferred grant liability247,000 
Term loan obligation, current3,590,0003,976,000
Total current liabilities10,399,00010,727,000
Noncurrent operating lease liability59,00085,000
Deferred grant liability 1,924,000
Total liabilities10,458,00012,736,000
Commitments and contingencies (Note 8)
Stockholders' deficit:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,952 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 4,522,656 and 4,264,231 issued and outstanding at March 31, 2024, and 4,522,656 issued and 4,444,097 outstanding as of December 31, 2023, respectively5,0005,000
Treasury stock (at cost, 258,425 and 78,559 shares as of March 31, 2024 and December 31, 2023, respectively)(500,000)(126,000)
Additional paid-in capital479,420,000479,274,000
Accumulated deficit(483,762,000)(480,501,000)
Total stockholders' deficit(4,837,000)(1,348,000)
Total liabilities and stockholders' deficit$ 5,621,000$ 11,388,000

About Plus Therapeutics Inc

PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
 CEO
 WEBSITEhttps://plustherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES17

Plus Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Plus Therapeutics Inc? What does PSTV stand for in stocks?

PSTV is the stock ticker symbol of Plus Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Plus Therapeutics Inc (PSTV)?

As of Fri May 17 2024, market cap of Plus Therapeutics Inc is 9.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSTV stock?

You can check PSTV's fair value in chart for subscribers.

What is the fair value of PSTV stock?

You can check PSTV's fair value in chart for subscribers. The fair value of Plus Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Plus Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PSTV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Plus Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PSTV is over valued or under valued. Whether Plus Therapeutics Inc is cheap or expensive depends on the assumptions which impact Plus Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSTV.

What is Plus Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PSTV's PE ratio (Price to Earnings) is -0.8 and Price to Sales (PS) ratio is 32.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSTV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Plus Therapeutics Inc's stock?

In the past 10 years, Plus Therapeutics Inc has provided -0.592 (multiply by 100 for percentage) rate of return.